Antibody Contract Manufacturing Market Size And Forecast 2026–2030: Trends Driving Industry Expansion
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Antibody Contract Manufacturing Market Size Forecast: How Big Could The Market Get By 2030?
The antibody contract manufacturing market has experienced rapid expansion in recent years. It is projected to increase from $16.79 billion in 2025 to $19.32 billion in 2026, at a compound annual growth rate (CAGR) of 15.0%. This growth observed in the past can be attributed to rising biologics development pipelines, increased outsourcing by biopharmaceutical companies, the expansion of mammalian cell culture platforms, growing clinical trial activity for antibodies, and the availability of specialized cmo infrastructure.
The antibody contract manufacturing market is anticipated to experience significant expansion over the coming years. This market is projected to reach $34.72 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.8%. This expansion during the projection period stems from factors such as increasing demand for commercial-scale antibody manufacturing, heightened investments in advanced biologics, a greater emphasis on manufacturing models that are cost-effective, the broadening of personalized medicine pipelines, and a rise in regulatory approvals for antibody-based therapies. Key trends anticipated during this period encompass the enlargement of large-scale antibody production capabilities, increasing integration of single-use bioprocessing technologies, a burgeoning demand for bispecific antibodies and ADCs, a sharpened focus on adaptable and scalable manufacturing approaches, and an elevated commitment to regulatory adherence and quality management.
Get A Free Sample Report With In-Depth Market Insights:
Antibody Contract Manufacturing Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The increasing volume of clinical trials is projected to fuel the expansion of the antibody contract manufacturing market moving ahead. These trials involve human participants in research to assess the safety and efficacy of novel medical treatments, interventions, or diagnostic methods. As the count of clinical trials utilizing antibody-based therapeutics or diagnostics grows, the demand for high-quality antibodies rises, necessitating a prompt and compliant supply for these trials. For example, data from May 2023, provided by ClinicalTrials.gov, an entity of the National Institutes of Health (NIH) – a US-based government agency overseeing medical research – revealed a surge in registered clinical trial studies across all 50 states of the United States and 221 countries, increasing from 399,499 in 2022 to 437,533 in 2023. Furthermore, approximately 241,498 studies, representing 53% of the total, were recorded outside the United States, whereas 140,492 studies (31%) were registered solely within the United States. Consequently, the increasing volume of clinical trials is stimulating the expansion of the antibody contract manufacturing market.
Antibody Contract Manufacturing Market Segmentation: How Does The Market Break Down By Category?
The antibody contract manufacturing market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Polyclonal Antibodies, Other Products
2) By Source: Mammalian, Microbial
3) By Scale Of Operation: Preclinical, Clinical, Commercial
4) By End-User: Biopharmaceutical Companies, Research Laboratories, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Therapeutic Monoclonal Antibodies, Diagnostic Monoclonal Antibodies
2) By Polyclonal Antibodies: Research Polyclonal Antibodies, Therapeutic Polyclonal Antibodies
3) By Other Products: Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Fusion Proteins
Antibody Contract Manufacturing Market Innovation Trends Shaping Future Development
Leading companies in the antibody contract manufacturing market are concentrating on innovations such as single-use technology, which minimizes cross-contamination risks and reduces operational costs. Single-use technology (SUT) refers to disposable components and systems utilized in biopharmaceutical manufacturing processes. For instance, in September 2024, Merck & Co., a US-based pharmaceutical company, launched the Mobius ADC Reactor, specifically designed to enhance the manufacturing of antibody-drug conjugates. This novel single-use reactor, created for antibody drug conjugate manufacturing, significantly boosts production efficiency by 70% compared to traditional stainless steel or glass methods. Its single-use nature reduces cross-contamination risks and operational expenses, allowing for quicker turnaround times. Additionally, advanced film technology improves bag strength and leak resistance, thereby safeguarding the integrity of highly potent active pharmaceutical ingredients. This innovation supports biopharmaceutical companies in producing critical therapies more safely and efficiently.
Antibody Contract Manufacturing Market Competitive Overview And Top Companies
Major companies operating in the antibody contract manufacturing market are Lonza Group AG, Catalent Inc, Samsung Biologics Co Ltd, Wuxi Biologics Cayman Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim BioXcellence, AGC Biologics, FUJIFILM Diosynth Biotechnologies, AbbVie Inc, Charles River Laboratories International Inc, mAbxience, KBI Biopharma Inc, Abzena Ltd, Just-Evotec Biologics, Northway Biotech, Cerbios-Pharma, Scorpius BioManufacturing, Lotte Biologics, Rentschler Biopharma SE, Cytiva (Life Sciences CDMO), Xcellon Biologics, Celonic AG, Syngene International Ltd
View The Full Antibody Contract Manufacturing Market Report:
Antibody Contract Manufacturing Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the antibody contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
